---
title: "Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285220001.md"
description: "Wedbush analyst David Nierengarten has reaffirmed a Buy rating on Nuvation Bio (NUVB) with a price target of $11.00. Nierengarten, a 5-star analyst, has an average return of 19.1% and a success rate of 49.79%. The analyst consensus for Nuvation Bio is Strong Buy, with a price target consensus of $13.17."
datetime: "2026-05-05T13:47:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285220001.md)
  - [en](https://longbridge.com/en/news/285220001.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285220001.md)
---

# Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)

Wedbush analyst David Nierengarten maintained a Buy rating on Nuvation Bio today and set a price target of $11.00.

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Nierengarten is a 5-star analyst with an average return of 19.1% and a 49.79% success rate. Nierengarten covers the Healthcare sector, focusing on stocks such as Nuvation Bio, Perspective Therapeutics, and Spyre Therapeutics.

Nuvation Bio has an analyst consensus of Strong Buy, with a price target consensus of $13.17.

### Related Stocks

- [NUVB.US](https://longbridge.com/en/quote/NUVB.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [CATX.US](https://longbridge.com/en/quote/CATX.US.md)
- [SYRE.US](https://longbridge.com/en/quote/SYRE.US.md)
- [NUVB+.US](https://longbridge.com/en/quote/NUVB+.US.md)

## Related News & Research

- [Roth MKM Sticks to Their Buy Rating for Capricor Therapeutics (CAPR)](https://longbridge.com/en/news/286497683.md)
- [Leerink Partners Sticks to Their Buy Rating for Ibio (IBIO)](https://longbridge.com/en/news/286588262.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)
- [Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer](https://longbridge.com/en/news/286428001.md)
- [MiNK Therapeutics' Q1 net loss narrows slightly](https://longbridge.com/en/news/286558132.md)